Predictive modeling of in vivo response to gemcitabine in pancreatic cancer.
A clear contradiction exists between cytotoxic in-vitro studies demonstrating effectiveness of Gemcitabine to curtail pancreatic cancer and in-vivo studies failing to show Gemcitabine as an effective treatment. The outcome of chemotherapy in metastatic stages, where surgery is no longer viable, show...
Main Authors: | James J Lee, Justin Huang, Christopher G England, Lacey R McNally, Hermann B Frieboes |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS Computational Biology |
Online Access: | http://europepmc.org/articles/PMC3777914?pdf=render |
Similar Items
-
Pancreatic Cancer Chemoresistance to Gemcitabine
by: Manoj Amrutkar, et al.
Published: (2017-11-01) -
Predictive Values of Blood-Based RNA Signatures for the Gemcitabine Response in Advanced Pancreatic Cancer
by: David Piquemal, et al.
Published: (2020-10-01) -
TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
by: Jia Cao, et al.
Published: (2015-01-01) -
Actively Targeted Nanodelivery of Echinomycin Induces Autophagy-Mediated Death in Chemoresistant Pancreatic Cancer In Vivo
by: Alexandra Thomas, et al.
Published: (2020-08-01) -
Gemcitabine Combination Nano Therapies for Pancreatic Cancer
by: Kamalika Samanta, et al.
Published: (2019-11-01)